Vanguard Group Inc. Has $44.36 Million Stake in ImmunityBio, Inc. (NASDAQ:IBRX)

Vanguard Group Inc. grew its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 2.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,328,229 shares of the company's stock after acquiring an additional 425,713 shares during the period. Vanguard Group Inc. owned 2.49% of ImmunityBio worth $44,360,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of IBRX. State Street Corp grew its holdings in shares of ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company's stock worth $32,195,000 after purchasing an additional 790,408 shares during the last quarter. Clearwater Capital Advisors LLC raised its position in ImmunityBio by 75.4% in the 4th quarter. Clearwater Capital Advisors LLC now owns 846,419 shares of the company's stock worth $2,167,000 after purchasing an additional 363,870 shares during the last quarter. Barclays PLC lifted its holdings in ImmunityBio by 127.4% during the 3rd quarter. Barclays PLC now owns 361,036 shares of the company's stock worth $1,344,000 after buying an additional 202,248 shares in the last quarter. LPL Financial LLC increased its stake in shares of ImmunityBio by 67.2% in the 4th quarter. LPL Financial LLC now owns 257,449 shares of the company's stock valued at $659,000 after buying an additional 103,495 shares during the period. Finally, XTX Topco Ltd raised its position in shares of ImmunityBio by 309.4% during the third quarter. XTX Topco Ltd now owns 92,910 shares of the company's stock worth $346,000 after acquiring an additional 70,215 shares during the last quarter. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Stock Down 2.2 %

NASDAQ IBRX traded down $0.06 during trading on Thursday, reaching $2.43. 1,304,646 shares of the stock traded hands, compared to its average volume of 6,476,203. The stock's 50-day moving average price is $2.98 and its 200 day moving average price is $3.51. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -2.64 and a beta of 0.51. ImmunityBio, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.53.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million. Analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and set a $8.00 price objective on shares of ImmunityBio in a report on Wednesday. BTIG Research assumed coverage on shares of ImmunityBio in a research note on Friday, January 10th. They issued a "buy" rating and a $6.00 price objective on the stock. Finally, D. Boral Capital reiterated a "buy" rating and set a $30.00 target price on shares of ImmunityBio in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $12.19.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.